Align Technology ((ALGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Align Technology is conducting a clinical study titled ‘Hyrax Vs. Invisalign Palatal Expander Clinical Study’ to compare the expansion results and overall experience between the Invisalign Palatal Expander and the Hyrax expander. This study aims to address conditions such as malocclusions and narrow maxillary arches, which are significant in orthodontic treatment.
The study tests two interventions: the Removable Rapid Palatal Expander, used with Invisalign, and the Banded Palatal Expander, known as Hyrax. Both are devices designed to expand the palate, but they differ in application methods.
This interventional study is randomized with a parallel assignment model and no masking, focusing primarily on treatment. Such a design ensures unbiased comparison between the two devices.
The study began on October 22, 2024, with the latest update on December 2, 2024. These dates indicate the study’s active recruitment phase, which is crucial for data collection and subsequent analysis.
For investors, this study could impact Align Technology’s stock performance by potentially enhancing its product offerings and competitive position in the orthodontic market. The outcome may influence investor sentiment, especially if the Invisalign expander shows favorable results compared to traditional methods.
The study is ongoing, with further details available on the ClinicalTrials portal.